A Phase 1/2 interventional study of vopimetostat and ERAS-0015 in PDAC, PDAC - Pancreatic Ductal Adenocarcinoma and NSCLC, sponsored by Tango Therapeutics, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Tango Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
TNG462-C103 is a Phase 1/2 study to investigate the safety and antitumor activity of vopimetostat (TNG462) combined with ERAS-0015 in patients with MTAP-null pancreatic or MTAP-null non-small cell lung cancer with RAS mutation.
TNG462-C103 is a Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat (PRMT5 inhibitor) in Combination with ERAS-0015 (pan-RAS molecular glue) in Patients with MTAP-null Pancreatic Cancer and MTAP-null Non-Small Cell Lung Cancer with RAS Mutation.
The study will be conducted in patients with MTAP- null pancreatic adenocarcinoma (PDAC) or locally advanced or metastatic MTAP loss non-small cell lung cancer (NSCLC) with RAS mutation in 2 parts: Phase 1 (dose escalation) and Phase 2 (dose expansion).
Individual arms in dose expansion may open once the MTD and/or RD(s) has been determined for the corresponding combination in dose escalation.
5,422 studies on the registry are indexed under Lung Neoplasms; 1,346 are open to participants now.
This study's planned enrollment of 188 is above the median of 60 across 3,656 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Tango Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has one of the following disease characteristics:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating doses of vopimetostat in combination with ERAS-0015
Drug: vopimetostat · Drug: ERAS-0015
Expansion arm at the RD(s) of vopimetostat in combination with ERAS-0015
Drug: vopimetostat · Drug: ERAS-0015
Expansion arm at the RD(s) of vopimetostat in combination with ERAS-0015
Drug: vopimetostat · Drug: ERAS-0015
Expansion arm at the RD(s) of vopimetostat in combination with ERAS-0015
Drug: vopimetostat · Drug: ERAS-0015
MTA-cooperative PRMT5 inhibitor
Pan-RAS molecular glue
Phase 1 Maximum Tolerated Dose
To determine the MTD and RD(s) of vopimetostat in combination with ERAS-0015
Time frame: 21 days
Phase 2 Combination Anti-neoplastic Activity
To assess antitumor activity- ORR of vopimetostat in combination with ERAS-0015
Time frame: 12 weeks
Phase 1 and 2 Combination Anti-neoplastic Activity
To assess antitumor activity of vopimetostat in combination with ERAS-0015
Time frame: 12 weeks
Phase 1 and 2 PK Profile of vopimetostat and ERAS-0015 in Combination
To characterize the PK profile of vopimetostat and ERAS-0015 when taken in combination
Time frame: 21 days
Phase 1 and 2 Adverse Event Profile
To determine the safety and tolerability of vopimetostat in combination with ERAS-0015
Time frame: 21 days
No study locations are listed for this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pan-RAS Molecular Glue ERAS-0015
Tango Therapeutics, Inc.